Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-09-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-1147PMID 27663587PMCID PMC5354973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Islet Cell Tumors of the Pancreas.

  2016cited by this paper
• ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma

  2016cited by this paper
• Molecular mechanisms of activity and derepression of alternative lengthening of telomeres

  2015cited by this paper
• Neuroendocrine tumors, version 1.2015.

  2015cited by this paper
• Clinicopathologic and Prognostic Significance of Multiple Hormone Expression in Pancreatic Neuroendocrine Tumors

  2015cited by this paper
• Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.

  2015cited by this paper
• Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

  2015cited by this paper
• KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine Tumors

  2014cited by this paper
• Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.

  2014influential reference
• Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.

  2014cited by this paper
• Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.

  2014influential reference
• Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production

  2012cited by this paper
• Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors

  2012cited by this paper
• Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

  2012cited by this paper
• Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes.

  2011cited by this paper
• Altered Telomeres in Tumors with ATRX and DAXX Mutations

  2011cited by this paper
• DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

  2011influential reference
• WHO Classification of Tumours of the Digestive System

  2010cited by this paper
• Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers

  2010cited by this paper
• Telomeres: protecting chromosomes against genome instability

  2010cited by this paper
• Neuronal subtype identity in the rat auditory brainstem as defined by molecular profile and axonal projection

  2009cited by this paper
• Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution

  2008cited by this paper
• Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

  2008cited by this paper
• Prognostic Score Predicting Survival After Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients

  2008influential reference
• Clinical outcome and long‐term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas

  2008cited by this paper
• Surgery for primary pancreatic neuroendocrine tumors

  2006cited by this paper
• Neuroendocrine Tumours of the Pancreas: Predictors of Survival after Surgical Treatment

  2005cited by this paper
• Differences in Survival by Histologic Type of Pancreatic Cancer

  2005cited by this paper
• A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.

  2005cited by this paper
• Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Islet cell tumors of the pancreas.

  1969cited by this paper
• Tumors of the pancreas.

  1951cited by this paper

• Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping

  2026cites this paper
• Alternative Lengthening of Telomeres in Malignant PEComas: Correlation with Molecular Features Including ATRX Gene Mutation Status.

  2026cites this paper
• From Pathology to Therapy: A Comprehensive Review of ATRX Mutation Related Molecular Functions and Disorders.

  2025cites this paper
• Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective.

  2025cites this paper
• Basic science and translational implications of current knowledge on neuroendocrine tumors

  2025cites this paper
• Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors

  2025cites this paper
• Alternative lengthening of telomeres and Ki‐67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors

  2025cites this paper
• Association of modifiable risk factors and telomere length with five neuroendocrine neoplasms: a bidirectional Mendelian randomization study

  2025cites this paper
• Telomere-related gene risk model predicts prognostic and immune microenvironment alterations in prostate cancer

  2025cites this paper
• Large-scale drug sensitivity, gene dependency, and proteogenomic analyses of telomere maintenance mechanisms in cancer cells

  2025cites this paper
• The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center Analysis.

  2025cites this paper
• Pancreatic neuroendocrine tumors - Bridging knowledge gaps for better outcomes.

  2025cites this paper
• Molecular Subtypes of Pancreatic Neuroendocrine Tumors Mutated in MEN1/DAXX/ATRX Explain Biological Variability

  2025cites this paper
• Differential diagnosis and predictive markers of pancreatic neuroendocrine tumours (PanNET)

  2025cites this paper
• Diagnostic value of SSTR2A, ATRX, and clusterin immunohistochemical expression in high-grade gastroenteropancreatic neuroendocrine neoplasms.

  2025cites this paper
• Distinct malignant cell states and myeloid glutamate signaling associated with aggressive pancreatic neuroendocrine tumors

  2025cites this paper
• Pancreatic neuroendocrine neoplasms: current paradigms and diagnostic challenges.

  2025cites this paper
• Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Non-Functional Pancreatic Neuroendocrine Tumors Correlate with Poor Patient Prognosis.

  2025cites this paper
• Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study

  2025cites this paper
• Diagnostic Pearls and Pitfalls in the Evaluation of Biopsies of the Pancreas.

  2024cites this paper
• Detection of Alternative Lengthening of Telomeres via Chromogenic in situ Hybridization (ALT-CISH) for the Prognostication of PanNETs and Other Neoplasms.

  2024cites this paper
• Mechanisms of Alternative Lengthening of Telomeres.

  2024cites this paper
• Molecular Basis of Pancreatic Neuroendocrine Tumors

  2024cites this paper
• Prognostic and predictive significance of p53 and ATRX in neuroendocrine neoplasms of GIT and pancreas and their utility as an adjunct to accurate diagnosis—An eight-year retrospective study

  2024cites this paper
• Genomic analysis defines distinct pancreatic and neuronal subtypes of lung carcinoid

  2024cites this paper
• Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.

  2024cites this paper
• Gradual telomere shortening in the tumorigenesis of pancreatic and hepatic mucinous cystic neoplasms.

  2024cites this paper
• ARX, PDX1, ISL1 and CDX2 expression distinguishes five subgroups of PanNETs with correlations to histology, hormone expression and outcome.

  2024cites this paper
• ss of ATRX and DAXX in pancreatic neuroendocrine tumors: association with recurrence risk, cellular phenotype, and heterogeneity.

  2024cites this paper
• Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor.

  2024cites this paper
• Radiologic tumor border can further stratify prognosis in patients with pancreatic neuroendocrine tumor.

  2024cites this paper
• Germline Testing identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.

  2024cites this paper
• Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?

  2024cites this paper
• Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns

  2024cites this paper
• Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).

  2023cites this paper
• The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia

  2023cites this paper
• Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer

  2023cites this paper
• Genetic and epigenetic prognosticators of neuroendocrine tumours of the GI tract, liver, biliary tract and pancreas: A systematic review and meta‐analysis

  2023cites this paper
• Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT)

  2023cites this paper
• Generation of an Obese Diabetic Mouse Model upon Conditional Atrx Disruption

  2023cites this paper
• The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer

  2023cites this paper
• Somatostatin receptor activity assessed by ^68Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors

  2023cites this paper
• Molecular alterations and therapeutic targets in pancreatic neuroendocrine tumors

  2023cites this paper
• Alpha Thalassemia/Intellectual Disability Syndrome X-Linked Expression Varies Significantly between Androgen Receptor-Positive and Androgen Receptor-Negative Prostatic Adenocarcinoma: Relation to Epidermal Growth Factor Receptor Expression and Clinicopathological Factors

  2023cites this paper
• Neoplastic Progression in Neuroendocrine Neoplasms of the Pancreas.

  2023cites this paper
• Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT)

  2023influential citation
• Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation

  2022cites this paper
• Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics

  2022cites this paper
• All Together Now: Standardization of Nomenclature for Neuroendocrine Neoplasms across Multiple Organs.

  2022cites this paper
• Maximum Value on Arterial Phase Computed Tomography Predicts Prognosis and Treatment Efficacy of Sunitinib for Pancreatic Neuroendocrine Tumours

  2022cites this paper
• From morphology to molecular targets—the pathologist’s view in diagnosing gastroenteropancreatic neuroendocrine neoplasms

  2022cites this paper
• Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies

  2022cites this paper
• Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy

  2022cites this paper
• Consequences of telomere replication failure: the other end-replication problem.

  2022cites this paper
• Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset

  2022cites this paper
• Combined Infiltrative Macroscopic Growth Pattern and Infiltrative Microscopic Tumor Border Status Is a Novel Surrogate Marker of Poor Prognosis in Patients With Pancreatic Neuroendocrine Tumor.

  2022cites this paper
• DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis

  2022cites this paper
• Necrosis is an independent predictor of disease-free and overall survival in pancreatic well-differentiated neuroendocrine tumours (NETs): a proposal to include it in grading systems.

  2022cites this paper
• The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs).

  2022cites this paper
• Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.

  2022cites this paper
• Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour

  2022cites this paper
• Consecutive Inhibition of Telomerase and Alternative Lengthening Pathway Promotes Hodgkin’s Lymphoma Cell Death

  2022cites this paper
• Genetics of Pancreatic Neuroendocrine Tumors.

  2022cites this paper
• Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?

  2021cites this paper
• Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites

  2021cites this paper
• Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors

  2021cites this paper
• Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors

  2021cites this paper
• Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus

  2021cites this paper
• Microscopic Invasion of Nerve Is Associated With Aggressive Behaviors in Pancreatic Neuroendocrine Tumors

  2021cites this paper
• Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

  2021cites this paper
• Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades

  2021cites this paper
• Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors

  2021cites this paper
• Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?

  2021cites this paper
• Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma

  2021cites this paper
• ALT Positivity in Human Cancers: Prevalence and Clinical Insights

  2021cites this paper
• Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis

  2021influential citation
• Prognostic biomarkers in pancreatic neuroendocrine tumors

  2021cites this paper
• Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?

  2021cites this paper
• G-quadruplexes mark alternative lengthening of telomeres

  2021cites this paper
• Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort

  2021cites this paper
• ALT neuroblastoma chemoresistance due to telomere dysfunction–induced ATM activation is reversible with ATM inhibitor AZD0156

  2021cites this paper
• Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review)

  2021cites this paper
• Clinical implications of cell‐of‐origin epigenetic characteristics in non‐functional pancreatic neuroendocrine tumors

  2021cites this paper
• Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.

  2021cites this paper
• MEN1-related PanNETs: identifying unmet clinical needs and future directives.

  2020influential citation
• New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms

  2020influential citation
• VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer

  2020cites this paper
• Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies

  2020cites this paper
• Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns

  2020cites this paper
• Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review

  2020cites this paper
• Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

  2020cites this paper
• An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin

  2020cites this paper
• Molecular-Genetic Features of Pancreatic Neuroendocrine Tumors

  2020cites this paper
• Telomere length alterations and ATRX/DAXX loss in pituitary adenomas

  2020cites this paper
• Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.

  2020cites this paper
• Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.

  2020cites this paper
• Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.

  2020cites this paper
• Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas

  2020cites this paper
• Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases.

  2020influential citation
• Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis

  2020cites this paper